(Barzolvolimab)Biosimilar Reference Antibody-GS40058 新品

货号：GS40058

Barzolvolimab is a humanized, anti-KIT (CD117) monoclonal antibody of the IgG1 isotype designed to selectively deplete tissue-resident mast cells and inhibit the stem cell factor (SCF)/KIT signaling pathway. It functions by binding to the extracellular domain of KIT with high affinity, which both blocks SCF-mediated activation and triggers antibody-dependent cellular cytotoxicity (ADCC) against mast cells. It is currently in clinical development (Phase II) for the treatment of chronic inducible urticaria (CindU), chronic spontaneous urticaria (CSU), eosinophilic esophagitis (EoE), and prurigo nodularis, conditions where mast cells and their mediators (like histamine) are central drivers of pathology.